Cardiff Oncology reports Q3 2026 results, preps Phase 3 onvansertib trial for Q1 2027Nov 16Clinical readoutBeiGeneCardiff OncologyUpdated
Cardiff Oncology posts results for terminated onvansertib pancreatic cancer trialNov 4Trial updateCardiff Oncology
HUTCHMED's Orpathys-Tagrisso filings for lung cancer accepted in Europe and JapanNov 2Clinical readoutAstraZenecaCardiff OncologyUpdated
Cardiff Oncology reports Q2 2026 results, plans Phase 3 mCRC trial for early 2027Aug 11Quarterly updateCardiff Oncology
Cardiff Oncology prices $10.05 million gross stock and warrant offeringJul 16FinancingCardiff Oncology